Breakthroughs happen when scientists are free to tackle problems from different angles and in different ways. Our scientists have this freedom.  

At Roche, we embrace the best technology and partnerships that work together to innovate to advance science and develop new medicines and diagnostics.

Our approach can be summed up in three words: diagnosis, development, delivery.

Blazing new trails in the medical science means pushing the boundaries of our knowledge and navigating unfamiliar terrain where no standard textbooks exist to provide guidance. Translating a molecule into a medicine that really matters for patients calls for the combined creativity and unrelenting perseverance of thousands of people with specialised knowledge in a broad range of areas. It is estimated that it takes 12 years, more than 7 million hours of work, over 6,000 experiments and around 400 researchers to journey from molecule to medicine.1

Roche Diagnostics has taken a leading role in supporting the UK Government in its response to the COVID-19 pandemic. We were the first to develop a test for COVID-19. We are first responders to global health crises, acting with speed, agility and innovation. Diagnostic solutions have been a central pillar to meeting the unprecedented challenge of COVID-19, with testing playing an important role in ensuring an effective, comprehensive and staged response to the outbreak. As we recover from the pandemic, our ambition is to play a leading role in integrating the wider pathology community to achieve better health outcomes for patients and public alike.

This passion for science means that every year over 500m* diagnostic tests are performed and 700,000 UK patients benefit from our treatments. 

We are supporting a number of Innovate UK initiatives in the Industrial Strategy Challenge Fund Data to Early Diagnosis programme, with £14.87 million investment over 5 projects across the UK.

And all of this stems from our innovation in science.  

Reference

  1. Data on file.
  2. This figure is estimated by combining the UK-based expenditure in Roche Products Limited 2017 statutory accounts with outsourced clinical spending in the UK funded by Roche Group.